Clover Health appoints Jamie Reynoso as CEO of Medicare Advantage and issues FY2023 partial guidance

CLOVER HEALTH INVESTMENTS, CORP. /DE

Appointed Jamie L. Reynoso as Chief Executive Officer of Medicare Advantage, effective January 6, 2023.
Issued partial FY2023 guidance: Insurance revenue $1.15B-$1.20B, Insurance MCR 89%-91%.
Andrew Toy to present at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.
Non-Insurance revenue guidance $0.75B-$0.80B, Non-Insurance MCR 98%-100%.
Strategic shift to prioritize profitability, expecting favorability in 2023 MCR and growth in Insurance top-line revenue.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jamie L. Reynoso

Chief Executive Officer of Medicare Advantage

CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DE

Effective: 2023-01-06
Filed: January 10, 2023, 6:59 PM ET

On January 6, 2023, the Board of Directors of Clover Health Investments, Corp. (the " Company ") appointed Jamie L. Reynoso Chief Executive Officer of Medicare Advantage, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jamie L. Reynoso was appointed as Chief Executive Officer of Medicare Advantage at CLOVER HEALTH INVESTMENTS, CORP. /DE.

Action: appointed
Role: Chief Executive Officer of Medicare Advantage

Exact text from the filing

On January 6, 2023, the Board of Directors of Clover Health Investments, Corp. (the " Company ") appointed Jamie L. Reynoso Chief Executive Officer of Medicare Advantage, effective immediately.

View on SEC.gov

CLOVER HEALTH INVESTMENTS, CORP. /DE filing history →

Source: SEC EDGAR

accession 0001801170-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.